Member Info for Toukankahmoon

BV

Ya got me. It’s only 5 years it just feels longer.

*************************************

Avacta Group plc Ordinary

Shares 10p 22/07/2020

-£4,918.75

Avacta Group plc Ordinary

Shares 10p 25/06/2020

-£2,999.20

Avacta Group plc Ordinary

Shares 10p

18/06/2020

-£1,999.79

Avacta Group plc Ordinary

Shares 10p 22/05/2020

-£4,999.22

Legal & General UK Index Class C - -£2,200.00

Accumulation (GBP)

15/04/2020 Settles 21/04/2020

B611689172

************************

Extract from my HL account records

BV you absolute saint give me an example from the last few days of my manufactured guff. As opposed to “we’ll never get the chance to buy at these prices again “ and other moronic stuff posted all the time by your “gang”.

Mea culpa. Here’s me thinking it was 2H25.

Or even at ESCO.

For the avoidance of doubt. I am happy with my fairly large (for me) investment in Avacta. I can see that CC is confident of great P1b results and that deals will be done off the back of that. I am happy that if there are delays to the results or securing deals that a backup financial lan is in place

But really I would expect nothing less from a well managed company.

Ice

BV

If you read all of what I posted and didn’t twist things you would know I said nothing of the sort.

I made it clear that the RNS doesn’t say things have slipped it just opens up the possibility of a slip to June. If you can’t see that then you haven’t understood the RNS.

And finally, mainly because of being too optimistic, I am just as far underwater as many on here who are being honest.

But heh you are just nasty people who have continually been shown to be wrong.

The good news is that the rest of this year looks good right now. But you won’t have read that because you are already writing your abusive response.

Thorn

Oops sorry. That sounded like a cheap shot at you. It wasn’t intended.

For the avoidance of doubt, of course I see yesterday’s RNS as a good thing. But not huge. And 6 years of being in this share has taught me that the communications have always hyped positive stuff and glossed over potential negative stuff. So it’s always worth reading between the lines.

Time will tell.

Now Thorn has gone all happy clappy it’s down to me to balance the debate.

I agree that Friday’s RNS is all reassuring stuff. But in the end it is just underlining that CC is making the progress she promised back in February. It’s been put out there to stop further SP slide.

The elephant in the room is that it is setting our expectations that P1b clinical data may not be published until June 2026. This isn’t disastrous but it’s yet another extension to timelines.

And don’t bother with all the name calling. Let’s take that as read. I am not saying P1b results will be delayed and I certainly don’t want them to be delayed. They could drop this year as predicted but then again . . .

Thompi

I agree that it is all reassuring stuff. But in the end it is just underlining that CC is making the progress she promised back in February. It’s been put out there to stop further SP slide.

The elephant in the room is that it is setting our expectations that P1b clinical data may not be published until June 2026. This isn’t disastrous but it’s yet another extension to timelines.

Watching

Please stop posting such baseless delusional ramps

I had no spare cash to put into HEMO. Kicking myself

Exactamundo

The news being better terms on the outstanding debt. Hardly earth shattering. The rest is just confirming (slightly delayed) progress on what was “promised” in Q1. Get a grip guys.

Dadas

I’m being thick here. How did Myles take part in the 30p equity raise?

BP will only make a deal when they are satisfied with the clinical trials results.

Safety net. Sums it up for me. Underlines progress being made that was predicted in February. Allows a couple more months grace for results publication. I don’t see a massive SP rise on the cards today. May be a day to buy more shares though. 👍😄

. . . good to see a more rational analysis of the RNS. And I agree that it is good news regarding finances though it doesn’t rule out a raise.

Regarding the science, it seems to be giving Avacta a bit more time to publish results of clinical trials, but most of us won’t be surprised if that slips to 2026 anyway. So all in all good news. The market will soon tell us if it is anyhow.

. . . it has to be in there in case they need to raise funds. It’s the only option that isn’t dependent on a third party. And so the ramping continues.

Benh

Pom Pom girl is not a swear word. Twa* is and it is not a nice thing to call somebody

Aldebaran

What do you care. You’re making a good profit on Hemo

Doh . . . it is a penny share

Be patient

Problem is that it is very difficult to predict the right time to buy for technology shares. Things can change very quickly.

Predicting the bottom as the SP slips downward takes a lot of experience and objective analysis. The delusional rampers in love with Avacta kept anticipating the bottom as the SP slipped all the way down from 240. Whereas others saved their cash until it was obvious that there had been a fundamental change in outlook. I missed the bottom , just, but I am much better off because I don’t waste money too soon. The rampers cannot bear the fact that some folks on here called it right. while they kept getting it wrong So they can only resort to potty mouthed character assassinations. They don’t care that they were wrong and we were right. That only makes them more angry and foul mouthed.

There is still a long way to go with Avacta. You can ignore me, green bin me or whatever. But if you’ve got any sense you’ll perhaps listen and consider a different view and save yourself some money.

End of rant.